Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00613132 | Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG | completed | Phase 1 | 78 | Annick DesjardinsOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00613223 | Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | completed | Phase 1 | 49 | Annick DesjardinsOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00735436 |
| A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) |
| terminated |
| Phase 2 |
| 18 |
| Duke UniversityOTHER |
| 1 |
| Feb 11, 2013 |
| clinicaltrials |
| NCT00004241 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00278382 | Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT01269411 | RO4929097 in Treating Patients With Recurrent Invasive Gliomas | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00016094 | S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 29, 2013 | clinicaltrials |
| NCT00089271 | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00003970 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00005856 | Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00006773 | Bortezomib in Treating Patients With Recurrent Glioma | terminated | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00075491 | Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme | terminated | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00077155 | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00098891 | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00354913 | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | completed | Phase 2 | 21 | Duke UniversityOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00005080 | 506U78 in Treating Patients With Lymphoma | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00110032 | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors | terminated | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00430079 | Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma | terminated | N/A | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT01579253 | Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients | unknown | — | 10 | Ludwig-Maximilians - University of MunichOTHER | 1 | Dec 18, 2012 | clinicaltrials |
| NCT00190424 | Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma | completed | Phase 2 | 80 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 13, 2012 | clinicaltrials |
| NCT00613054 | Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | completed | Phase 1 | 27 | Annick DesjardinsOTHER | 1 | Dec 5, 2012 | clinicaltrials |
| NCT00797940 | Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)(CLARITY-1) | withdrawn | Phase 2 | 0 | Sophiris Bio CorpINDUSTRY | 0 | Dec 3, 2012 | clinicaltrials |
| NCT01737346 | Procarbazine and Lomustine in Recurrent Glioblastoma | unknown | Phase 2 | 52 | Incheon St.Mary's HospitalOTHER | 1 | Dec 3, 2012 | clinicaltrials |
| NCT00734864 | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | withdrawn | Phase 1 | 0 | Annick DesjardinsOTHER | 1 | Nov 21, 2012 | clinicaltrials |
| NCT00606008 | A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT00409214 | Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma | completed | Phase 2 | 18 | Light Sciences OncologyINDUSTRY | 1 | Nov 16, 2012 | clinicaltrials |
| NCT01251484 | BIBF 1120 in Recurrent Glioblastoma Multiforme | completed | Phase 2 | 25 | Ulrik LassenOTHER | 1 | Oct 4, 2012 | clinicaltrials |
| NCT01043536 | Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults(SIB-IMRT) | completed | Phase 1 | 10 | Centre Georges Francois LeclercOTHER | 1 | Sep 25, 2012 | clinicaltrials |
| NCT00948389 | Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) | terminated | Phase 1 / Phase 2 | 28 | Bristol-Myers SquibbINDUSTRY | 4 | Aug 31, 2012 | clinicaltrials |
| NCT00272870 | Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy | terminated | Phase 1 | 1 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Aug 29, 2012 | clinicaltrials |
| NCT01294735 | Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1) | completed | Phase 1 | 19 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 15, 2012 | clinicaltrials |
| NCT01089868 | Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients | completed | — | 79 | Ludwig-Maximilians - University of MunichOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT01656980 | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | unknown | Phase 3 | 236 | Shandong Lanjin Pharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 3, 2012 | clinicaltrials |
| NCT01240460 | Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection | completed | Phase 1 | 40 | SanofiINDUSTRY | 1 | Jul 27, 2012 | clinicaltrials |
| NCT01637753 | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma | unknown | N/A | 212 | Shandong Lanjin Pharmaceuticals Co.,LtdINDUSTRY | 1 | Jul 11, 2012 | clinicaltrials |
| NCT00624728 | Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)(GLIO-TEP) | completed | Phase 1 / Phase 2 | 21 | University Hospital, BordeauxOTHER | 1 | May 4, 2012 | clinicaltrials |
| NCT00379470 | Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) | completed | Phase 3 | 236 | NovoCure Ltd.INDUSTRY | 7 | May 1, 2012 | clinicaltrials |
| NCT00704691 | Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas | terminated | Early Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00132158 | ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Apr 17, 2012 | clinicaltrials |
| NCT01285414 | Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 5 | Myrexis Inc.INDUSTRY | 1 | Apr 11, 2012 | clinicaltrials |
| NCT00777686 | Measuring Non-Enhancing Glioblastoma Progression | completed | — | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 30, 2012 | clinicaltrials |
| NCT00412542 | Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas | completed | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT01189513 | SCH-900105 in Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 20, 2012 | clinicaltrials |
| NCT00973557 | The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function | completed | — | 6 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00071539 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | completed | Phase 2 | 56 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | Jan 20, 2012 | clinicaltrials |
| NCT00508456 | Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM | terminated | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 16, 2012 | clinicaltrials |
| NCT00504660 | 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients | completed | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 11, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Feb 20, 2013source: clinicaltrials